Amid complaints about unilateral drug company restrictions on the 340B drug pricing program and mounting pressure from industry-backed advocates for even more 340B changes to favor drugmakers, a bipartisan group of six U.S. senators have taken a proactive step by asking for ideas to ensure “stability” for 340B. This move came in the form of a request for information (RFI) … [Read more...]
UPDATED: Drugmakers Cutting 340B Discounts Reported Record Revenues in 2021
January 13, 2023– Note: This story is updated to include information for Biogen, which announced 340B restrictions in December 2022. The 19 drug companies that have imposed restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought more than $660 billion in revenues in 2021. The banner year for the companies occurred as hospitals … [Read more...]
For Patients, Symptoms of Drugmaker 340B Restrictions Include Shortness of Breath, Hospitalization
Dec. 23, 2022— The examples of worsened health outcomes for patients from drug company restrictions on 340B pricing to safety-net hospitals continue to mount. At Riverside Regional Medical Center in Virginia, one discharged patient with diabetes was readmitted to the hospital within days due to delayed access to an insulin medication for which drug companies had restricted … [Read more...]
UPDATED: Drugmakers Cutting 340B Discounts Reported Record Revenues Last Year
August 24, 2022– Note: This story is updated to include information for additional drug companies that have imposed 340B restrictions since March 2022. The 18 drug companies that have imposed restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in nearly $650 billion in revenues in 2021. The banner year for the companies … [Read more...]
Faces of 340B: Community Pharmacy Restrictions Mean Worse Health Outcomes
July 13, 2022 – Pharmacist Hali Brown becomes frustrated when she thinks about all the patients in northeast Kansas who have been hurt by drug company restrictions on discounts to safety-net hospitals. For two years, Hali’s health system, Community HealthCare System (CHCSKS), has struggled to ensure patients can access the medications they need now that 18 drug companies have … [Read more...]
Congressional Champions Stand Up to Defend 340B
June 20, 2022— Members of the U.S. House of Representatives from both political parties went to the House floor recently to deliver a historic series of speeches honoring the upcoming 30th anniversary of the 340B drug pricing program and urging their colleagues to defend the program against unlawful attacks by drug companies. The lawmakers’ unified message was that 340B is … [Read more...]
340B Is Key in the Fight to End Viral Hepatitis
May 27, 2022 – In January 2021, the Department of Health and Human Services (HHS) published a strategic plan to eliminate viral hepatitis by 2030. Hospitals participating in the 340B drug pricing program are a key element of that ambitious goal. They are using their 340B savings to achieve measurable improvements in health outcomes for patients with hepatitis C. National … [Read more...]